{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:40:57Z","timestamp":1793724057882,"version":"4.6.1"},"reference-count":188,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s12026-022-09265-0","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T11:03:16Z","timestamp":1645527796000},"page":"289-315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review"],"prefix":"10.1007","volume":"70","author":[{"given":"Swarnali","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvrendu Sankar","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sovan","family":"Samanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhimli","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biplab","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5435-8556","authenticated-orcid":false,"given":"Sandeep Kumar","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"9265_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/bs.aivir.2018.01.001","volume":"100","author":"VM Corman","year":"2018","unstructured":"Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and sources of endemic human coronaviruses. Adv Virus Res. 2018;100:163\u201388. https:\/\/doi.org\/10.1016\/bs.aivir.2018.01.001.","journal-title":"Adv Virus Res"},{"issue":"2","key":"9265_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.14744\/ejmo.2020.90853","volume":"4","author":"A Hafeez","year":"2020","unstructured":"Hafeez A, Ahmad S, Siddqui SA, Ahmad M, Mishra S. A review of COVID-19 (coronavirus disease-2019) diagnosis, treatments and prevention. EJMO. 2020;4(2):116\u201325. https:\/\/doi.org\/10.14744\/ejmo.2020.90853.","journal-title":"EJMO"},{"issue":"76","key":"9265_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijsu.2020.02.034","volume":"2020","author":"C Sohrabi","year":"2019","unstructured":"Sohrabi C, Alsafi Z, O\u2019neill N, Khan M, Kerwan A, Al-Jabir A, Iosifidis C, Agha R. World Health Organization declares global emergency: a review of the novel coronavirus (COVID-19). Int J Surg. 2019;2020(76):71\u20136. https:\/\/doi.org\/10.1016\/j.ijsu.2020.02.034.","journal-title":"Int J Surg"},{"issue":"8","key":"9265_CR4","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"WJ Wiersinga","year":"2020","unstructured":"Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782\u201393. https:\/\/doi.org\/10.1001\/jama.2020.12839.","journal-title":"JAMA"},{"issue":"1","key":"9265_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.23750\/abm.v91i1.9397","volume":"91","author":"D Cucinotta","year":"2020","unstructured":"Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157. https:\/\/doi.org\/10.23750\/abm.v91i1.9397.","journal-title":"Acta Biomed"},{"key":"9265_CR6","unstructured":"World Health Organization. WHO coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int\/ (Accessed 19th December, 2020)."},{"issue":"3","key":"9265_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/cei.13582","volume":"204","author":"SC Jordan","year":"2021","unstructured":"Jordan SC. Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses. Clin Exp Immunol. 2021;204(3):310\u201320. https:\/\/doi.org\/10.1111\/cei.13582.","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"9265_CR8","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.jiph.2020.07.001","volume":"13","author":"MA Chowdhury","year":"2020","unstructured":"Chowdhury MA, Hossain N, Kashem MA, Shahid MA, Alam A. Immune response in COVID-19: a review. J Infect Public Health. 2020;13(11):1619\u201329. https:\/\/doi.org\/10.1016\/j.jiph.2020.07.001.","journal-title":"J Infect Public Health"},{"issue":"6","key":"9265_CR9","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.immuni.2020.05.004","volume":"52","author":"K Subbarao","year":"2020","unstructured":"Subbarao K, Mahanty S. Respiratory virus infections: understanding COVID-19. Immunity. 2020;52(6):905\u20139. https:\/\/doi.org\/10.1016\/j.immuni.2020.05.004.","journal-title":"Immunity"},{"key":"9265_CR10","doi-asserted-by":"publisher","unstructured":"Chen PL, Lee NY, Cia CT, Ko WC, Hsueh PR. A review of treatment of coronavirus disease 2019 (COVID-19): therapeutic repurposing and unmet clinical needs. Front Pharmacol. 2020;11https:\/\/doi.org\/10.3389\/fphar.2020.584956","DOI":"10.3389\/fphar.2020.584956"},{"issue":"18","key":"9265_CR11","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2020.6019","volume":"323","author":"JM Sanders","year":"2020","unstructured":"Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824\u201336. https:\/\/doi.org\/10.1001\/jama.2020.6019.","journal-title":"JAMA"},{"issue":"1","key":"9265_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-021-00327-2","volume":"6","author":"VM Kumar","year":"2021","unstructured":"Kumar VM, Pandi-Perumal SR, Trakht I, Thyagarajan SP. Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases. NPJ Vaccines. 2021;6(1):1\u20137. https:\/\/doi.org\/10.1038\/s41541-021-00327-2.","journal-title":"NPJ Vaccines"},{"key":"9265_CR13","doi-asserted-by":"publisher","first-page":"n196","DOI":"10.1136\/bmj.n196","volume":"372","author":"K Thiagarajan","year":"2021","unstructured":"Thiagarajan K. COVID-19: India is at centre of global vaccine manufacturing, but opacity threatens public trust. BMJ. 2021;372:n196. https:\/\/doi.org\/10.1136\/bmj.n196.","journal-title":"BMJ"},{"issue":"10255","key":"9265_CR14","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","volume":"396","author":"DY Logunov","year":"2020","unstructured":"Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia. The Lancet. 2020;396(10255):887\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(20)31866-3.","journal-title":"The Lancet"},{"issue":"4","key":"9265_CR15","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1128\/MMBR.69.4.635-664.2005","volume":"69","author":"SR Weiss","year":"2005","unstructured":"Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005;69(4):635\u201364. https:\/\/doi.org\/10.1128\/MMBR.69.4.635-664.2005.","journal-title":"Microbiol Mol Biol Rev"},{"issue":"4","key":"9265_CR16","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1177\/1010539520929223","volume":"32","author":"C Binns","year":"2020","unstructured":"Binns C, Low WY, Kyung LM. The COVID-19 pandemic: public health and epidemiology. Asia Pac J Public Health. 2020;32(4):140\u20134. https:\/\/doi.org\/10.1177\/1010539520929223.","journal-title":"Asia Pac J Public Health"},{"key":"9265_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727\u201333. https:\/\/doi.org\/10.1056\/NEJMoa2001017.","journal-title":"N Engl J Med"},{"issue":"4","key":"9265_CR18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.dsx.2020.04.020","volume":"14","author":"I Astuti","year":"2020","unstructured":"Astuti I. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes MetabSyndr: Clin Res Rev. 2020;14(4):407\u201312. https:\/\/doi.org\/10.1016\/j.dsx.2020.04.020.","journal-title":"Diabetes MetabSyndr: Clin Res Rev"},{"issue":"2","key":"9265_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jmii.2020.03.022","volume":"54","author":"L Mousavizadeh","year":"2021","unstructured":"Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: their roles in pathogenesis. J Microbiol Immunol Infect. 2021;54(2):159\u201363. https:\/\/doi.org\/10.1016\/j.jmii.2020.03.022.","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"9265_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","volume":"23","author":"CB Jackson","year":"2022","unstructured":"Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3\u201320. https:\/\/doi.org\/10.1038\/s41580-021-00418-x.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"9265_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jsb.2010.11.021","volume":"174","author":"BW Neuman","year":"2011","unstructured":"Neuman BW, Kiss G, Kunding AH, Bhella D, Baksh MF, Connelly S, Droese B, Klaus JP, Makino S, Sawicki SG, Siddell SG. A structural analysis of M protein in coronavirus assembly and morphology. J Struct Biol. 2011;174(1):11\u201322. https:\/\/doi.org\/10.1016\/j.jsb.2010.11.021.","journal-title":"J Struct Biol"},{"issue":"4","key":"9265_CR22","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1128\/JVI.01467-06","volume":"81","author":"ML DeDiego","year":"2007","unstructured":"DeDiego ML, \u00c1lvarez E, Almaz\u00e1n F, Rejas MT, Lamirande E, Roberts A, Shieh WJ, Zaki SR, Subbarao K, Enjuanes L. A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. J Virol. 2007;81(4):1701\u201313. https:\/\/doi.org\/10.1128\/JVI.01467-06.","journal-title":"J Virol"},{"key":"9265_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/frma.2020.595370","volume":"5","author":"J Mei","year":"2020","unstructured":"Mei J, Zhao D, Strotmann A. Intellectual structure of coronavirus research: a perspective from an author cocitation analysis. Front Res Metr. 2020;5:13. https:\/\/doi.org\/10.3389\/frma.2020.595370.","journal-title":"Front Res Metr"},{"issue":"21","key":"9265_CR24","doi-asserted-by":"publisher","first-page":"11727","DOI":"10.1073\/pnas.2003138117","volume":"117","author":"J Shang","year":"2020","unstructured":"Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, Li F. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci. 2020;117(21):11727\u201334. https:\/\/doi.org\/10.1073\/pnas.2003138117.","journal-title":"Proc Natl Acad Sci"},{"key":"9265_CR25","doi-asserted-by":"publisher","first-page":"111272","DOI":"10.1016\/j.biopha.2021.111272","volume":"12","author":"WG Dos Santos","year":"2021","unstructured":"Dos Santos WG. Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines. Biomed Pharmacother. 2021;12:111272. https:\/\/doi.org\/10.1016\/j.biopha.2021.111272.","journal-title":"Biomed Pharmacother"},{"issue":"13","key":"9265_CR26","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1001\/jama.2020.16656","volume":"324","author":"DS Stephens","year":"2020","unstructured":"Stephens DS, McElrath MJ. COVID-19 and the path to immunity. JAMA. 2020;324(13):1279\u201381. https:\/\/doi.org\/10.1001\/jama.2020.16656.","journal-title":"JAMA"},{"key":"9265_CR27","doi-asserted-by":"publisher","first-page":"109777","DOI":"10.1016\/j.mehy.2020.109777","volume":"140","author":"A Yaqinuddin","year":"2020","unstructured":"Yaqinuddin A, Kashir J. Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents. Med Hypotheses. 2020;140:109777. https:\/\/doi.org\/10.1016\/j.mehy.2020.109777.","journal-title":"Med Hypotheses"},{"issue":"4","key":"9265_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S1473-3099(20)30113-4","volume":"20","author":"Y Pan","year":"2020","unstructured":"Pan Y, Zhang D, Yang P, Poon LL, Wang Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis. 2020;20(4):411\u20132. https:\/\/doi.org\/10.1016\/S1473-3099(20)30113-4.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"9265_CR29","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","volume":"180","author":"C Wu","year":"2020","unstructured":"Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan. China JAMA Int Med. 2020;180(7):934\u201343. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0994.","journal-title":"China JAMA Int Med"},{"key":"9265_CR30","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.3389\/fimmu.2018.02379","volume":"9","author":"GP Amarante-Mendes","year":"2018","unstructured":"Amarante-Mendes GP, Adjemian S, Branco LM, Zanetti LC, Weinlich R, Bortoluci KR. Pattern recognition receptors and the host cell death molecular machinery. Front Immunol. 2018;9:2379. https:\/\/doi.org\/10.3389\/fimmu.2018.02379.","journal-title":"Front Immunol"},{"key":"9265_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jmv.27405","volume":"21","author":"M Manik","year":"2021","unstructured":"Manik M, Singh RK. Role of toll\u2010like receptors in modulation of cytokine storm signaling in SARS\u2010CoV\u20102\u2010induced COVID\u201019. J Med Virol. 2021;21:1\u20139. https:\/\/doi.org\/10.1002\/jmv.27405.","journal-title":"J Med Virol"},{"issue":"8","key":"9265_CR32","doi-asserted-by":"publisher","first-page":"FSO605","DOI":"10.2144\/fsoa-2020-0091","volume":"6","author":"O Livia","year":"2020","unstructured":"Livia O, Caraglia M, Facchini G, Margherita V, De Placido S, Buonerba C. Toll-like receptors and COVID-19: a two-faced story with an exciting ending. Future Sci OA. 2020;6(8):FSO605. https:\/\/doi.org\/10.2144\/fsoa-2020-0091.","journal-title":"Future Sci OA"},{"issue":"4","key":"9265_CR33","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","volume":"124","author":"S Akira","year":"2006","unstructured":"Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783\u2013801. https:\/\/doi.org\/10.1016\/j.cell.2006.02.015.","journal-title":"Cell"},{"key":"9265_CR34","doi-asserted-by":"crossref","unstructured":"Taefehshokr N, Taefehshokr S, Hemmat N, Heit B. COVID-19: perspectives on innate immune evasion. Frontiers in immunology. 2020;11.","DOI":"10.3389\/fimmu.2020.580641"},{"issue":"1","key":"9265_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4049\/jimmunol.2000413","volume":"205","author":"RH Manjili","year":"2020","unstructured":"Manjili RH, Zarei M, Habibi M, Manjili MH. COVID-19 as an acute inflammatory disease. J Immunol. 2020;205(1):12\u20139.","journal-title":"J Immunol"},{"issue":"5","key":"9265_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"T Kawai","year":"2010","unstructured":"Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373\u201384. https:\/\/doi.org\/10.1038\/ni.1863.","journal-title":"Nat Immunol"},{"issue":"10","key":"9265_CR37","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.2174\/1871530321666210225104819","volume":"21","author":"J Banerjee","year":"2021","unstructured":"Banerjee J, Dey S, Ali KM, Giri B, Dash SK. Advancements in adjuvanticity of bioactive inorganic and organic compounds. Endocr Metab Immune Disord. 2021;21(10):1721\u201343. https:\/\/doi.org\/10.2174\/1871530321666210225104819.","journal-title":"Endocr Metab Immune Disord"},{"key":"9265_CR38","doi-asserted-by":"publisher","unstructured":"de Marcken M, Dhaliwal K, Danielsen AC, Gautron AS, Dominguez-Villar M. TLR7 and TLR8 activate distinct pathways in monocytes during RNA virus infection. Sci Signal. 2019; 29;12(605). https:\/\/doi.org\/10.1126\/scisignal.aaw1347","DOI":"10.1126\/scisignal.aaw1347"},{"issue":"8","key":"9265_CR39","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/s41587-020-0602-4","volume":"38","author":"RL Chua","year":"2020","unstructured":"Chua RL, Lukassen S, Trump S, Hennig BP, Wendisch D, Pott F, Debnath O, Th\u00fcrmann L, Kurth F, V\u00f6lker MT, Kazmierski J. COVID-19 severity correlates with airway epithelium\u2013immune cell interactions identified by single-cell analysis. Nat Biotechnol. 2020;38(8):970\u20139. https:\/\/doi.org\/10.1038\/s41587-020-0602-4.","journal-title":"Nat Biotechnol"},{"key":"9265_CR40","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.virol.2015.02.017","volume":"479","author":"AM Kell","year":"2015","unstructured":"Kell AM, Gale M Jr. RIG-I in RNA virus recognition. Virology. 2015;479:110\u201321. https:\/\/doi.org\/10.1016\/j.virol.2015.02.017.","journal-title":"Virology"},{"issue":"7522","key":"9265_CR41","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nature13590","volume":"514","author":"D Goubau","year":"2014","unstructured":"Goubau D, Schlee M, Deddouche S, Pruijssers AJ, Zillinger T, Goldeck M, Schuberth C, Van der Veen AG, Fujimura T, Rehwinkel J, Iskarpatyoti JA. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5\u2032-diphosphates. Nature. 2014;514(7522):372\u20135. https:\/\/doi.org\/10.1038\/nature13590.","journal-title":"Nature"},{"issue":"1","key":"9265_CR42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3349\/ymj.2016.57.1.5","volume":"57","author":"YK Kim","year":"2016","unstructured":"Kim YK, Shin JS, Nahm MH. NOD-like receptors in infection, immunity, and diseases. Yonsei Med J. 2016;57(1):5\u201314. https:\/\/doi.org\/10.3349\/ymj.2016.57.1.5.","journal-title":"Yonsei Med J"},{"issue":"1","key":"9265_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/diseases9010017","volume":"9","author":"EM Kozlov","year":"2021","unstructured":"Kozlov EM, Ivanova E, Grechko AV, Wu WK, Starodubova AV, Orekhov AN. Involvement of oxidative stress and the innate immune system in SARS-CoV-2 infection. Diseases. 2021;9(1):17. https:\/\/doi.org\/10.3390\/diseases9010017.","journal-title":"Diseases"},{"issue":"02","key":"9265_CR44","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/s-0036-1572553","volume":"37","author":"TP Charles","year":"2016","unstructured":"Charles TP, Shellito JE. Human immunodeficiency virus infection and host defense in the lungs. Semin Respir Crit Care Med. 2016;37(02):147\u201356. https:\/\/doi.org\/10.1055\/s-0036-1572553.","journal-title":"Semin Respir Crit Care Med"},{"issue":"7","key":"9265_CR45","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nri2103","volume":"7","author":"JA Villadangos","year":"2007","unstructured":"Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol. 2007;7(7):543\u201355. https:\/\/doi.org\/10.1038\/nri2103.","journal-title":"Nat Rev Immunol"},{"key":"9265_CR46","doi-asserted-by":"publisher","unstructured":"Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. From innate immunity to immunological memory. 2006:17\u201358. https:\/\/doi.org\/10.1007\/3-540-32636-7_2","DOI":"10.1007\/3-540-32636-7_2"},{"issue":"2","key":"9265_CR47","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.4049\/jimmunol.182.2.1099","volume":"182","author":"L Cervantes-Barrag\u00e1n","year":"2009","unstructured":"Cervantes-Barrag\u00e1n L, Kalinke U, Z\u00fcst R, K\u00f6nig M, Reizis B, L\u00f3pez-Mac\u00edas C, Thiel V, Ludewig B. Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection. J Immunol. 2009;182(2):1099\u2013106. https:\/\/doi.org\/10.4049\/jimmunol.182.2.1099.","journal-title":"J Immunol"},{"issue":"5","key":"9265_CR48","doi-asserted-by":"publisher","first-page":"e36837","DOI":"10.1371\/journal.pone.0036837","volume":"7","author":"A Glasner","year":"2012","unstructured":"Glasner A, Zurunic A, Meningher T, LenacRovis T, Tsukerman P, Bar-On Y, Yamin R, Meyers AF, Mandeboim M, Jonjic S, Mandelboim O. Elucidating the mechanisms of influenza virus recognition by Ncr1. PLoS ONE. 2012;7(5):e36837. https:\/\/doi.org\/10.1371\/journal.pone.0036837.","journal-title":"PLoS ONE"},{"issue":"5","key":"9265_CR49","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","volume":"17","author":"M Zheng","year":"2020","unstructured":"Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, Xu Y, Tian Z. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533\u20135. https:\/\/doi.org\/10.1038\/s41423-020-0402-2.","journal-title":"Cell Mol Immunol"},{"key":"9265_CR50","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fimmu.2020.01662","volume":"11","author":"A Guihot","year":"2020","unstructured":"Guihot A, Litvinova E, Autran B, Debr\u00e9 P, Vieillard V. Cell-mediated immune responses to COVID-19 infection. Front Immunol. 2020;11:1662. https:\/\/doi.org\/10.3389\/fimmu.2020.01662.","journal-title":"Front Immunol"},{"issue":"6669","key":"9265_CR51","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/35869","volume":"391","author":"VM Braud","year":"1998","unstructured":"Braud VM, Allan DS, O\u2019Callaghan CA, S\u00f6derstr\u00f6m K, D\u2019Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, Lanier LL. HLA-E binds to natural killer cell receptors CD94\/NKG2A. B and C Nature. 1998;391(6669):795\u20139. https:\/\/doi.org\/10.1038\/35869.","journal-title":"B and C Nature"},{"key":"9265_CR52","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fphys.2018.00113","volume":"9","author":"C Rosales","year":"2018","unstructured":"Rosales C. Neutrophil: a cell with many roles in inflammation or several cell types. Front Physiol. 2018;9:113. https:\/\/doi.org\/10.3389\/fphys.2018.00113.","journal-title":"Front Physiol"},{"issue":"2","key":"9265_CR53","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s11239-020-02324-z","volume":"51","author":"Y Zuo","year":"2021","unstructured":"Zuo Y, Zuo M, Yalavarthi S, Gockman K, Madison JA, Shi H, Woodard W, Lezak SP, Lugogo NL, Knight JS, Kanthi Y. Neutrophil extracellular traps and thrombosis in COVID-19. J Thromb Thrombolysis. 2021;51(2):446\u201353. https:\/\/doi.org\/10.1007\/s11239-020-02324-z.","journal-title":"J Thromb Thrombolysis"},{"key":"9265_CR54","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.3389\/fimmu.2021.714511","volume":"12","author":"YM Ali","year":"2021","unstructured":"Ali YM, Ferrari M, Lynch NJ, Yaseen S, Dudler T, Gragerov S, Demopulos G, Heeney JL, Schwaeble WJ. Lectin pathway mediates complement activation by SARS-CoV-2 proteins. Front Immunol. 2021;12:2645. https:\/\/doi.org\/10.3389\/fimmu.2021.714511.","journal-title":"Front Immunol"},{"key":"9265_CR55","doi-asserted-by":"publisher","unstructured":"Jarlhelt I, Nielsen SK, Jahn CX, Hansen CB, P\u00e9rez-Al\u00f3s L, Rosbjerg A, Bayarri-Olmos R, Skjoedt MO, Garred P. SARS-CoV-2 antibodies mediate complement and cellular driven inflammation. Front. Immunol. 2021;12. https:\/\/doi.org\/10.3389\/fimmu.2021.767981","DOI":"10.3389\/fimmu.2021.767981"},{"issue":"5","key":"9265_CR56","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1172\/JCI137244","volume":"1 130","author":"G Chen","year":"2020","unstructured":"Chen G, Wu DI, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Investig. 2020;1 130(5):2620\u20139. https:\/\/doi.org\/10.1172\/JCI137244.","journal-title":"J Clin Investig"},{"key":"9265_CR57","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jcv.2019.08.009","volume":"119","author":"JM Jansen","year":"2019","unstructured":"Jansen JM, Gerlach T, Elbahesh H, Rimmelzwaan GF, Saletti G. Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination. J Clin Virol. 2019;119:44\u201352. https:\/\/doi.org\/10.1016\/j.jcv.2019.08.009.","journal-title":"J Clin Virol"},{"issue":"1","key":"9265_CR58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1146\/annurev.immunol.19.1.23","volume":"19","author":"MK Jenkins","year":"2001","unstructured":"Jenkins MK, Khoruts A, Ingulli E, Mueller DL, McSorley SJ, Reinhardt RL, Itano A, Pape KA. In vivo activation of antigen-specific CD4 T cells. Annu Rev Immunol. 2001;19(1):23\u201345. https:\/\/doi.org\/10.1146\/annurev.immunol.19.1.23.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"9265_CR59","doi-asserted-by":"publisher","first-page":"a006049","DOI":"10.1101\/cshperspect.a006049","volume":"4","author":"K Newton","year":"2012","unstructured":"Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol. 2012;4(3):a006049. https:\/\/doi.org\/10.1101\/cshperspect.a006049.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"9265_CR60","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14(1):36\u201349. https:\/\/doi.org\/10.1038\/nri3581.","journal-title":"Nat Rev Immunol"},{"key":"9265_CR61","doi-asserted-by":"publisher","unstructured":"Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, Nakao C. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021; 371(6529). https:\/\/doi.org\/10.1126\/science.abf4063","DOI":"10.1126\/science.abf4063"},{"issue":"7","key":"9265_CR62","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1111\/all.14364","volume":"75","author":"AK Azkur","year":"2020","unstructured":"Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Br\u00fcggen MC, O\u2019Mahony L, Gao Y, Nadeau K, Akdis CA. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75(7):1564\u201381. https:\/\/doi.org\/10.1111\/all.14364.","journal-title":"Allergy"},{"issue":"15","key":"9265_CR63","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/cid\/ciaa310","volume":"71","author":"L Guo","year":"2020","unstructured":"Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020;71(15):778\u201385. https:\/\/doi.org\/10.1093\/cid\/ciaa310.","journal-title":"Clin Infect Dis"},{"key":"9265_CR64","doi-asserted-by":"publisher","unstructured":"Yu HQ, Sun BQ, Fang ZF, Zhao JC, Liu XY, Li YM, Sun XZ, Liang HF, Zhong B, Huang ZF, Zheng PY. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur Respir J. 2020; 56(2). https:\/\/doi.org\/10.1183\/13993003.01526-2020","DOI":"10.1183\/13993003.01526-2020"},{"issue":"9","key":"9265_CR65","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00134-020-06157-5","volume":"46","author":"S Fourati","year":"2020","unstructured":"Fourati S, Hue S, Pawlotsky JM, Mekontso-Dessap A, de Prost N. SARS-CoV-2 viral loads and serum IgA\/IgG immune responses in critically ill COVID-19 patients. Intensive Care Med. 2020;46(9):1781\u20133. https:\/\/doi.org\/10.1007\/s00134-020-06157-5.","journal-title":"Intensive Care Med"},{"issue":"13","key":"9265_CR66","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1001\/jama.2020.16656","volume":"6 324","author":"DS Stephens","year":"2020","unstructured":"Stephens DS, McElrath MJ. COVID-19 and the path to immunity. Jama. 2020;6 324(13):1279\u20138. https:\/\/doi.org\/10.1001\/jama.2020.16656.","journal-title":"Jama"},{"issue":"1","key":"9265_CR67","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri.2017.106","volume":"18","author":"LL Lu","year":"2018","unstructured":"Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. 2018;18(1):46\u201361. https:\/\/doi.org\/10.1038\/nri.2017.106.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"9265_CR68","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.3389\/fimmu.2020.01949","volume":"7","author":"VK Shah","year":"2020","unstructured":"Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. Overview of immune response during SARS-CoV-2 infection: lessons from the past. Front Immunol. 2020;7(11):1949. https:\/\/doi.org\/10.3389\/fimmu.2020.01949.","journal-title":"Front Immunol"},{"issue":"7","key":"9265_CR69","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L, Jadi RS, Marrama D. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489\u2013501. https:\/\/doi.org\/10.1016\/j.cell.2020.05.015.","journal-title":"Cell"},{"issue":"6","key":"9265_CR70","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","volume":"20","author":"M Merad","year":"2020","unstructured":"Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355\u201362. https:\/\/doi.org\/10.1038\/s41577-020-0331-4.","journal-title":"Nat Rev Immunol"},{"issue":"7807","key":"9265_CR71","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","volume":"581","author":"J Shang","year":"2020","unstructured":"Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221\u20134. https:\/\/doi.org\/10.1038\/s41586-020-2179-y.","journal-title":"Nature"},{"key":"9265_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11684-020-0754-0","volume":"12","author":"X Zou","year":"2020","unstructured":"Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;12:1\u20138. https:\/\/doi.org\/10.1007\/s11684-020-0754-0.","journal-title":"Front Med"},{"key":"9265_CR73","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ijid.2020.04.027","volume":"96","author":"H Zhang","year":"2020","unstructured":"Zhang H, Li HB, Lyu JR, Lei XM, Li W, Wu G, Lyu J, Dai ZM. Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection. Int J Infect Dis. 2020;96:19\u201324. https:\/\/doi.org\/10.1016\/j.ijid.2020.04.027.","journal-title":"Int J Infect Dis"},{"issue":"12","key":"9265_CR74","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.it.2020.10.004","volume":"41","author":"AG Harrison","year":"2020","unstructured":"Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 2020;41(12):1100\u201315. https:\/\/doi.org\/10.1016\/j.it.2020.10.004.","journal-title":"Trends Immunol"},{"issue":"6","key":"9265_CR75","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nrmicro2147","volume":"7","author":"S Perlman","year":"2009","unstructured":"Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. 2009;7(6):439\u201350. https:\/\/doi.org\/10.1038\/nrmicro2147.","journal-title":"Nat Rev Microbiol"},{"issue":"12","key":"9265_CR76","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1128\/JVI.02501-05","volume":"80","author":"EJ Snijder","year":"2006","unstructured":"Snijder EJ, Van Der Meer Y, Zevenhoven-Dobbe J, Onderwater JJ, Van Der Meulen J, Koerten HK, Mommaas AM. Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex. J Virol. 2006;80(12):5927\u201340. https:\/\/doi.org\/10.1128\/JVI.02501-05.","journal-title":"J Virol"},{"issue":"27","key":"9265_CR77","doi-asserted-by":"publisher","first-page":"12257","DOI":"10.1073\/pnas.1000378107","volume":"107","author":"HY Wu","year":"2010","unstructured":"Wu HY, Brian DA. Subgenomic messenger RNA amplification in coronaviruses. Proc Natl Acad Sci U S A. 2010;107(27):12257\u201362. https:\/\/doi.org\/10.1073\/pnas.1000378107.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"9265_CR78","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","volume":"20","author":"MZ Tay","year":"2020","unstructured":"Tay MZ, Poh CM, R\u00e9nia L, MacAry PA, Ng LF. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363\u201374. https:\/\/doi.org\/10.1038\/s41577-020-0311-8.","journal-title":"Nat Rev Immunol"},{"key":"9265_CR79","doi-asserted-by":"publisher","first-page":"102836","DOI":"10.1016\/j.ebiom.2020.102836","volume":"57","author":"TR Martin","year":"2020","unstructured":"Martin TR, Wurfel MM, Zanoni I, Ulevitch R. Targeting innate immunity by blocking CD14: novel approach to control inflammation and organ dysfunction in COVID-19 illness. EBio Med. 2020;57:102836. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102836.","journal-title":"EBio Med"},{"issue":"2","key":"9265_CR80","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/cei.13523","volume":"202","author":"S Amor","year":"2020","unstructured":"Amor S, Fern\u00e1ndez Blanco L, Baker D. Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage. Clin Exp Immunol. 2020;202(2):193\u2013209. https:\/\/doi.org\/10.1111\/cei.13523.","journal-title":"Clin Exp Immunol"},{"key":"9265_CR81","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1016\/j.csbj.2021.07.023","volume":"19","author":"YQ Min","year":"2021","unstructured":"Min YQ, Huang M, Sun X, Deng F, Wang H, Ning YJ. Immune evasion of SARS-CoV-2 from interferon antiviral system. Comput Struct Biotechnol J. 2021;19:4217\u201325. https:\/\/doi.org\/10.1016\/j.csbj.2021.07.023.","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"9265_CR82","doi-asserted-by":"publisher","first-page":"e8729","DOI":"10.1371\/journal.pone.0008729","volume":"5","author":"T Yoshikawa","year":"2010","unstructured":"Yoshikawa T, Hill TE, Yoshikawa N, Popov VL, Galindo CL, Garner HR, Peters CJ, Tseng CT. Dynamic innate immune responses of human bronchial epithelial cells to severe acute respiratory syndrome-associated coronavirus infection. PLoS ONE. 2010;5(1):e8729. https:\/\/doi.org\/10.1371\/journal.pone.0008729.","journal-title":"PLoS ONE"},{"issue":"8","key":"9265_CR83","doi-asserted-by":"publisher","first-page":"e1009800","DOI":"10.1371\/journal.ppat.1009800","volume":"17","author":"M Shemesh","year":"2021","unstructured":"Shemesh M, Aktepe TE, Deerain JM, McAuley JL, Audsley MD, David CT, Purcell DF, Urin V, Hartmann R, Moseley GW, Mackenzie JM. SARS-CoV-2 suppresses IFN\u03b2 production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon. PLoSPathog. 2021;17(8):e1009800. https:\/\/doi.org\/10.1371\/journal.ppat.1009800.","journal-title":"PLoSPathog"},{"issue":"1","key":"9265_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-17665-9","volume":"11","author":"X Lei","year":"2020","unstructured":"Lei X, Dong X, Ma R, Wang W, Xiao X, Tian Z, Wang C, Wang Y, Li L, Ren L, Guo F. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun. 2020;11(1):1\u20132. https:\/\/doi.org\/10.1038\/s41467-020-17665-9.","journal-title":"Nat Commun"},{"key":"9265_CR85","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3389\/fimmu.2019.00325","volume":"10","author":"CA Jefferies","year":"2019","unstructured":"Jefferies CA. Regulating IRFs in IFN driven disease. Front Immunol. 2019;10:325. https:\/\/doi.org\/10.3389\/fimmu.2019.00325.","journal-title":"Front Immunol"},{"issue":"2","key":"9265_CR86","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/cmi.2013.61","volume":"11","author":"KL Siu","year":"2014","unstructured":"Siu KL, Chan CP, Kok KH, Woo PC, Jin DY. Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain. Cell Mol Immunol. 2014;11(2):141\u20139. https:\/\/doi.org\/10.1038\/cmi.2013.61.","journal-title":"Cell Mol Immunol"},{"key":"9265_CR87","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cytogfr.2020.06.001","volume":"54","author":"VJ Costela-Ruiz","year":"2020","unstructured":"Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodr\u00edguez L. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62\u201375. https:\/\/doi.org\/10.1016\/j.cytogfr.2020.06.001.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"7821","key":"9265_CR88","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","volume":"584","author":"C Lucas","year":"2020","unstructured":"Lucas C, Wong P, Klein J, Castro TB, Silva J, Sundaram M, Ellingson MK, Mao T, Oh JE, Israelow B, Takahashi T. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463\u20139. https:\/\/doi.org\/10.1038\/s41586-020-2588-y.","journal-title":"Nature"},{"issue":"10223","key":"9265_CR89","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395(10223):497\u2013506. https:\/\/doi.org\/10.1016\/S0140-6736(20)30183-5.","journal-title":"China Lancet"},{"issue":"5","key":"9265_CR90","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.immuni.2020.04.003","volume":"19 52","author":"T Hirano","year":"2020","unstructured":"Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity. 2020;19 52(5):731\u20133. https:\/\/doi.org\/10.1016\/j.immuni.2020.04.003.","journal-title":"Immunity"},{"key":"9265_CR91","doi-asserted-by":"publisher","unstructured":"Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Sun R, Tian Z, Xu X, Wei H. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. BioRxiv.2020 Jan 1. https:\/\/doi.org\/10.1093\/nsr\/nwaa041","DOI":"10.1093\/nsr\/nwaa041"},{"issue":"1","key":"9265_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep34310","volume":"6","author":"WH Yeap","year":"2016","unstructured":"Yeap WH, Wong KL, Shimasaki N, Teo EC, Quek JK, Yong HX, Diong CP, Bertoletti A, Linn YC, Wong SC. CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes. Sci Rep. 2016;6(1):1\u201322. https:\/\/doi.org\/10.1038\/srep34310.","journal-title":"Sci Rep"},{"issue":"6490","key":"9265_CR93","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.abb8925","volume":"368","author":"JB Moore","year":"2020","unstructured":"Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473\u20134. https:\/\/doi.org\/10.1126\/science.abb8925.","journal-title":"Science"},{"issue":"4","key":"9265_CR94","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/jmv.25685","volume":"92","author":"G Li","year":"2020","unstructured":"Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, Pan P, Wang W, Hu D, Liu X, Zhang Q. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424\u201332. https:\/\/doi.org\/10.1002\/jmv.25685.","journal-title":"J Med Virol"},{"key":"9265_CR95","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-1-62703-523-1_7","volume":"1040","author":"M Rayamajhi","year":"2013","unstructured":"Rayamajhi M, Zhang Y, Miao EA. Detection of pyroptosis by measuring released lactate dehydrogenase activity. Methods Mol Biol. 2013;1040:85\u201390. https:\/\/doi.org\/10.1007\/978-1-62703-523-1_7.","journal-title":"Methods Mol Biol"},{"issue":"4","key":"9265_CR96","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","volume":"8","author":"Z Xu","year":"2020","unstructured":"Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420\u20132. https:\/\/doi.org\/10.1016\/S2213-2600(20)30076-X.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"9265_CR97","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/jth.14768","volume":"18","author":"N Tang","year":"2020","unstructured":"Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J ThrombHaemost. 2020;18(4):844\u20137. https:\/\/doi.org\/10.1111\/jth.14768.","journal-title":"J ThrombHaemost"},{"key":"9265_CR98","doi-asserted-by":"publisher","unstructured":"Java A, Apicelli AJ, Liszewski MK, Coler-Reilly A, Atkinson JP, Kim AH, Kulkarni HS. The complement system in COVID-19: friend and foe?. JCI insight. 2020; 6: 5(15). https:\/\/doi.org\/10.1172\/jci.insight.140711","DOI":"10.1172\/jci.insight.140711"},{"issue":"1","key":"9265_CR99","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jaci.2020.05.006","volume":"146","author":"M Cugno","year":"2020","unstructured":"Cugno M, Meroni PL, Gualtierotti R, Griffini S, Grovetti E, Torri A, Panigada M, Aliberti S, Blasi F, Tedesco F, Peyvandi F. Complement activation in patients with COVID-19: a novel therapeutic target. J Allergy Clin Immunol. 2020;146(1):215. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.006.","journal-title":"J Allergy Clin Immunol"},{"issue":"14","key":"9265_CR100","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1111\/bph.15187","volume":"178","author":"S Jodele","year":"2021","unstructured":"Jodele S, K\u00f6hl J. Tackling COVID-19 infection through complement-targeted immunotherapy. Br J Pharmacol. 2021;178(14):2832\u201348. https:\/\/doi.org\/10.1111\/bph.15187.","journal-title":"Br J Pharmacol"},{"key":"9265_CR101","doi-asserted-by":"publisher","first-page":"108598","DOI":"10.1016\/j.clim.2020.108598","volume":"220","author":"DC Mastellos","year":"2020","unstructured":"Mastellos DC, da Silva BG, Fonseca BA, Fonseca NP, Auxiliadora-Martins M, Mastaglio S, Ruggeri A, Sironi M, Radermacher P, Chrysanthopoulou A, Skendros P. Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy. Clin Immunol. 2020;220:108598. https:\/\/doi.org\/10.1016\/j.clim.2020.108598.","journal-title":"Clin Immunol"},{"key":"9265_CR102","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1101\/2020.02.23.20026690","volume":"26","author":"M Liao","year":"2020","unstructured":"Liao M, Liu Y, Yuan J, et al. The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing. Nat Med. 2020;26:842\u20134. https:\/\/doi.org\/10.1101\/2020.02.23.20026690.","journal-title":"Nat Med"},{"issue":"1","key":"9265_CR103","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41421-020-0168-9","volume":"6","author":"W Wen","year":"2020","unstructured":"Wen W, Su W, Tang H, et al. Immune cell profiling of COVID-19 patients in the recovery stageby single-cell sequencing. Cell Discov. 2020;6(1):31. https:\/\/doi.org\/10.1038\/s41421-020-0168-9.","journal-title":"Cell Discov"},{"issue":"6","key":"9265_CR104","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.chom.2020.04.009","volume":"27","author":"EJ Giamarellos-Bourboulis","year":"2020","unstructured":"Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992\u20131000. https:\/\/doi.org\/10.1016\/j.chom.2020.04.009.","journal-title":"Cell Host Microbe"},{"key":"9265_CR105","doi-asserted-by":"publisher","unstructured":"Diao B, Wang C, Tan Y. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020; 11(827). https:\/\/doi.org\/10.3389\/fimmu.2020.00827","DOI":"10.3389\/fimmu.2020.00827"},{"issue":"3","key":"9265_CR106","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3390\/v11030243","volume":"11","author":"EA van Erp","year":"2019","unstructured":"van Erp EA, van Kampen MR, van Kasteren PB, et al. Viral infection of human natural killer cells. Viruses. 2019;11(3):243. https:\/\/doi.org\/10.3390\/v11030243.","journal-title":"Viruses"},{"issue":"1","key":"9265_CR107","doi-asserted-by":"publisher","first-page":"108590","DOI":"10.1101\/2020.07.23.20161182","volume":"34","author":"C Yao","year":"2021","unstructured":"Yao C, Bora SA, Parimon T, Zaman T, Friedman OA, Palatinus JA, Surapaneni NS, Matusov YP, Chiang GC, Kassar AG, Patel N. Cell-type-specific immune dysregulation in severely ill COVID-19 patients. Cell Rep. 2021;34(1):108590. https:\/\/doi.org\/10.1101\/2020.07.23.20161182.","journal-title":"Cell Rep"},{"key":"9265_CR108","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.3389\/fimmu.2020.01949","volume":"11","author":"VK Shah","year":"2020","unstructured":"Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. Overview of immune response during SARS-CoV-2 infection: lessons from the past. Front Immunol. 2020;11:1949. https:\/\/doi.org\/10.3389\/fimmu.2020.01949.","journal-title":"Front Immunol"},{"key":"9265_CR109","first-page":"28","volume":"18","author":"YL Lau","year":"2012","unstructured":"Lau YL, Peiris J, Law HKW, et al. Role of dendritic cells in SARS coronavirus infection. Hong Kong Med J. 2012;18:28\u201330.","journal-title":"Hong Kong Med J"},{"key":"9265_CR110","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","volume":"586","author":"F Krammer","year":"2020","unstructured":"Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516\u201327. https:\/\/doi.org\/10.1038\/s41586-020-2798-3.","journal-title":"Nature"},{"key":"9265_CR111","unstructured":"World Health Organization. DRAFT landscape of COVID-19 candidate vaccines. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines Accessed 4 March 2020."},{"key":"9265_CR112","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.3389\/fimmu.2020.585354","volume":"11","author":"O Sharma","year":"2020","unstructured":"Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020;11:2413. https:\/\/doi.org\/10.3389\/fimmu.2020.585354.","journal-title":"Front Immunol"},{"key":"9265_CR113","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.3389\/fphar.2020.590154","volume":"11","author":"P Dash","year":"2021","unstructured":"Dash P, Mohapatra S, Ghosh S, Nayak B. A scoping insight on potential prophylactics, vaccines and therapeutic weaponry for the ongoing novel coronavirus (COVID-19) pandemic-a comprehensive review. Front Pharmacol. 2021;11:2471. https:\/\/doi.org\/10.3389\/fphar.2020.590154.","journal-title":"Front Pharmacol"},{"issue":"10","key":"9265_CR114","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","volume":"20","author":"M Jeyanathan","year":"2020","unstructured":"Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20(10):615\u201332. https:\/\/doi.org\/10.1038\/s41577-020-00434-6.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"9265_CR115","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2020.15543","volume":"8 324","author":"S Xia","year":"2020","unstructured":"Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. Jama. 2020;8 324(10):951\u201360. https:\/\/doi.org\/10.1001\/jama.2020.15543.","journal-title":"Jama"},{"key":"9265_CR116","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.smim.2018.10.010","volume":"40","author":"A Ciabattini","year":"2018","unstructured":"Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. Vaccination in the elderly: the challenge of immune changes with aging. Semin Immunol. 2018;40:83\u201394. https:\/\/doi.org\/10.1016\/j.smim.2018.10.010.","journal-title":"Semin Immunol"},{"key":"9265_CR117","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/IDR.S288877","volume":"14","author":"TM Belete","year":"2021","unstructured":"Belete TM. Review on up-to-date status of candidate vaccines for COVID-19 disease. Infect Drug Resist. 2021;14:151. https:\/\/doi.org\/10.2147\/IDR.S288877.","journal-title":"Infect Drug Resist"},{"key":"9265_CR118","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jceh.2020.06.003","volume":"10","author":"MS Khuroo","year":"2020","unstructured":"Khuroo MS, Khuroo M, Khuroo MS, Sofi AA, Khuroo NS. COVID-19 vaccines: a race against time in the middle of death and devastation. J Clin Exp Hepatol. 2020;10:610\u201321. https:\/\/doi.org\/10.1016\/j.jceh.2020.06.003.","journal-title":"J Clin Exp Hepatol"},{"key":"9265_CR119","doi-asserted-by":"publisher","first-page":"198114","DOI":"10.1016\/j.virusres.2020.198114","volume":"288","author":"SP Kaur","year":"2020","unstructured":"Kaur SP, Gupta V. COVID-19 vaccine: a comprehensive status report. Virus Res. 2020;288:198114. https:\/\/doi.org\/10.1016\/j.virusres.2020.198114.","journal-title":"Virus Res"},{"issue":"3","key":"9265_CR120","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","volume":"182","author":"L Dai","year":"2020","unstructured":"Dai L, Zheng T, Xu K, Han Y, Xu L, Huang E, An Y, Cheng Y, Li S, Liu M, Yang M. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell. 2020;182(3):722\u201333. https:\/\/doi.org\/10.1016\/j.cell.2020.06.035.","journal-title":"Cell"},{"key":"9265_CR121","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijpharm.2008.04.036","volume":"364","author":"Y Perrie","year":"2008","unstructured":"Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm. 2008;364:272\u201380. https:\/\/doi.org\/10.1016\/j.ijpharm.2008.04.036.","journal-title":"Int J Pharm"},{"key":"9265_CR122","doi-asserted-by":"publisher","first-page":"e05007","DOI":"10.1016\/j.heliyon.2020.e05007","volume":"19","author":"R Piyush","year":"2020","unstructured":"Piyush R, Rajarshi K, Chatterjee A, Khan R, Ray S. Nucleic acid-based therapy for coronavirus disease 2019. Heliyon. 2020;19:e05007. https:\/\/doi.org\/10.1016\/j.heliyon.2020.e05007.","journal-title":"Heliyon"},{"key":"9265_CR123","doi-asserted-by":"publisher","unstructured":"Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ. An mRNA vaccine against SARS-CoV-2\u2014preliminary report. N\u00a0Engl J Med. 2020;14. https:\/\/doi.org\/10.1056\/NEJMoa2022483","DOI":"10.1056\/NEJMoa2022483"},{"key":"9265_CR124","doi-asserted-by":"publisher","first-page":"e924700","DOI":"10.12659\/MSM.924700","volume":"26","author":"F Wang","year":"2020","unstructured":"Wang F, Kream RM, Stefano GB. An evidence based perspective on mRNA-SARS-CoV-2 vaccine development. Med Sci Monit. 2020;26:e924700-1. https:\/\/doi.org\/10.12659\/MSM.924700.","journal-title":"Med Sci Monit"},{"key":"9265_CR125","doi-asserted-by":"publisher","unstructured":"Walsh EE, Frenck R, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. Medrxiv. 2020 https:\/\/doi.org\/10.1056\/NEJMoa2027906","DOI":"10.1056\/NEJMoa2027906"},{"key":"9265_CR126","unstructured":"ClinicalTrials.gov.\u00a0Identifier: NCT04336410. 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04336410. Accessed May2, 2020"},{"key":"9265_CR127","doi-asserted-by":"crossref","unstructured":"Saini P. COVID-19 pandemic: potential phase III vaccines in development. T Appl Biol Chem J. 2020;1(1):21-33. https:\/\/doi.org\/10.52679\/tabcj.2020.0004","DOI":"10.52679\/tabcj.2020.0004"},{"key":"9265_CR128","doi-asserted-by":"publisher","unstructured":"Thiagarajan K. What do we know about India\u2019s Covaxin vaccine?. BMJ: British Medical Journal (Online). 2021 Apr 20;373. https:\/\/doi.org\/10.1136\/bmj.n997","DOI":"10.1136\/bmj.n997"},{"issue":"6\u20137","key":"9265_CR129","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.micinf.2020.05.001","volume":"22","author":"N Zhang","year":"2020","unstructured":"Zhang N, Li C, Hu Y, Li K, Liang J, Wang L, Du L, Jiang S. Current development of COVID-19 diagnostics, vaccines and therapeutics. Microbes Infect. 2020;22(6\u20137):231\u20135. https:\/\/doi.org\/10.1016\/j.micinf.2020.05.001.","journal-title":"Microbes Infect"},{"issue":"10","key":"9265_CR130","first-page":"523","volume":"10","author":"JS Gharate","year":"2021","unstructured":"Gharate JS, Daitkar SA, Aher KA. Approved COVID 19 vaccines: a review. World J Pharm Res. 2021;10(10):523\u201342.","journal-title":"World J Pharm Res"},{"key":"9265_CR131","doi-asserted-by":"publisher","unstructured":"Vogel FR. Improving vaccine performance with adjuvants. Clin Infect Dis. 2000; 30(Supplement_3):S266\u201370. https:\/\/doi.org\/10.1086\/313883","DOI":"10.1086\/313883"},{"key":"9265_CR132","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.3389\/fimmu.2020.589833","volume":"11","author":"Z Liang","year":"2020","unstructured":"Liang Z, Zhu H, Wang X, Jing B, Li Z, Xia X, Sun H, Yang Y, Zhang W, Shi L, Zeng H. Adjuvants for coronavirus vaccines Front Immunol. 2020;11:2896. https:\/\/doi.org\/10.3389\/fimmu.2020.589833.","journal-title":"Adjuvants for coronavirus vaccines Front Immunol"},{"issue":"44","key":"9265_CR133","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.1016\/j.vaccine.2021.09.055","volume":"39","author":"AK Singh","year":"2021","unstructured":"Singh AK, Phatak SR, Singh R, Bhattacharjee K, Singh NK, Gupta A, Sharma A. Antibody response after first and second-dose of ChAdOx1-nCOV (CovishieldTM\u00ae) and BBV-152 (CovaxinTM\u00ae) among health care workers in India: the final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. Vaccine. 2021;39(44):6492\u2013509. https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.055.","journal-title":"Vaccine"},{"issue":"2","key":"9265_CR134","first-page":"191","volume":"8","author":"RB Malabadi","year":"2021","unstructured":"Malabadi RB, Meti NT, Chalannavar RK. Applications of nanotechnology in vaccine development for coronavirus (SARS-CoV-2) disease (Covid-19). Int J Res Sci Inno. 2021;8(2):191\u20138.","journal-title":"Int J Res Sci Inno"},{"key":"9265_CR135","doi-asserted-by":"publisher","unstructured":"Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881\u201391. https:\/\/doi.org\/10.1016\/S0140-6736(21)00432-3.","DOI":"10.1016\/S0140-6736(21)00432-3"},{"key":"9265_CR136","doi-asserted-by":"publisher","first-page":"n997","DOI":"10.1136\/bmj.n997","volume":"373","author":"K Thiagarajan","year":"2021","unstructured":"Thiagarajan K. What do we know about India\u2019s Covaxin vaccine. bmj. 2021;373:n997. https:\/\/doi.org\/10.1136\/bmj.n997.","journal-title":"bmj"},{"key":"9265_CR137","doi-asserted-by":"publisher","first-page":"17","DOI":"10.22159\/ajpcr.2021v14i5.41061","volume":"7","author":"SK Misra","year":"2021","unstructured":"Misra SK, Pathak K, Pathak D, Yadav R. Current updates on COVID-19 vaccines. Asian J Pharm Clin Res. 2021;7:17\u201323. https:\/\/doi.org\/10.22159\/ajpcr.2021v14i5.41061.","journal-title":"Asian J Pharm Clin Res"},{"key":"9265_CR138","unstructured":"World Health Organization. Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN\u00ae vaccine against COVID-19: interim guidance, 3 November 2021."},{"issue":"7","key":"9265_CR139","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","volume":"21","author":"R Ella","year":"2021","unstructured":"Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, Das D, Raju D, Praturi U, Sapkal G, Yadav P, Reddy P, Verma S, Singh C, Redkar SV, Gillurkar CS, Kushwaha JS, Mohapatra S, Bhate A, Rai S, Panda S, Abraham P, Gupta N, Ella K, Bhargava B, Vadrevu KM. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021;21(7):950\u201361. https:\/\/doi.org\/10.1016\/S1473-3099(21)00070-0.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"9265_CR140","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","volume":"21","author":"R Ella","year":"2021","unstructured":"Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, Ganneru B, Sapkal G, Yadav P, Abraham P, Panda S, Gupta N, Reddy P, Verma S, Kumar Rai S, Singh C, Redkar SV, Gillurkar CS, Kushwaha JS, Mohapatra S, Rao V, Guleria R, Ella K, Bhargava B. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a doubleblind, randomised, phase 1 trial. Lancet Infect Dis. 2021;21(5):637\u201346. https:\/\/doi.org\/10.1016\/S1473-3099(20)30942-7.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"9265_CR141","doi-asserted-by":"publisher","first-page":"102298","DOI":"10.1016\/j.isci.2021.102298","volume":"24","author":"B Ganneru","year":"2021","unstructured":"Ganneru B, Jogdand H, Daram VK, Das D, Molugu NR, Prasad SD, Kannappa SV, Ella KM, Ravikrishnan R, Awasthi A, Jose J. Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation. Iscience. 2021;24(4):102298. https:\/\/doi.org\/10.1016\/j.isci.2021.102298.","journal-title":"Iscience"},{"key":"9265_CR142","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3389\/fimmu.2020.01441","volume":"11","author":"LF Garc\u00eda","year":"2020","unstructured":"Garc\u00eda LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020;11:1441. https:\/\/doi.org\/10.3389\/fimmu.2020.01441.","journal-title":"Front Immunol"},{"key":"9265_CR143","doi-asserted-by":"publisher","first-page":"685711","DOI":"10.1146\/annurev.immunol.21.120601.141040","volume":"21","author":"RM Steinman","year":"2003","unstructured":"Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu rev immunol. 2003;21:685711. https:\/\/doi.org\/10.1146\/annurev.immunol.21.120601.141040.","journal-title":"Annu rev immunol"},{"issue":"3","key":"9265_CR144","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1365-2567.2007.02719.x","volume":"123","author":"GE Kaiko","year":"2008","unstructured":"Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunology. 2008;123(3):326\u201338. https:\/\/doi.org\/10.1111\/j.1365-2567.2007.02719.x.","journal-title":"Immunology"},{"issue":"6","key":"9265_CR145","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1006\/smim.1993.1050","volume":"5","author":"AK Abbas","year":"1993","unstructured":"Abbas AK, Burstein HJ, Bogen SA. Determinants of helper T cell-dependent antibody production. Semin Immunol. 1993;5(6):441\u20137. https:\/\/doi.org\/10.1006\/smim.1993.1050.","journal-title":"Semin Immunol"},{"issue":"4","key":"9265_CR146","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1152\/advan.00066.2013","volume":"37","author":"ND Pennock","year":"2013","unstructured":"Pennock ND, White JT, Cross EW, Cheney EE, Tamburini BA, Kedl RM. T cell responses: naive to memory and everything in between. Adv Physiol Educ. 2013;37(4):273\u201383. https:\/\/doi.org\/10.1152\/advan.00066.2013.","journal-title":"Adv Physiol Educ"},{"issue":"3","key":"9265_CR147","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.immuni.2007.09.002","volume":"21 27","author":"T D\u00f6rner","year":"2007","unstructured":"D\u00f6rner T, Radbruch A. Antibodies and B cell memory in viral immunity. Immunity. 2007;21 27(3):384\u201392. https:\/\/doi.org\/10.1016\/j.immuni.2007.09.002.","journal-title":"Immunity"},{"key":"9265_CR148","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet. 2020;396:467\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(20)31604-4.","journal-title":"Lancet"},{"key":"9265_CR149","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.3389\/fimmu.2020.579250","volume":"11","author":"KL Flanagan","year":"2020","unstructured":"Flanagan KL, Best E, Crawford NW, Giles M, Koirala A, Macartney K, Russell F, Teh BW, Wen SC. Progress and pitfalls in the quest for effective SARS-CoV-2 (COVID-19) vaccines. Front Immunol. 2020;11:2410. https:\/\/doi.org\/10.3389\/fimmu.2020.579250.","journal-title":"Front Immunol"},{"issue":"4","key":"9265_CR150","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3390\/immuno1040032","volume":"1","author":"K Goyal","year":"2021","unstructured":"Goyal K, Goel H, Baranwal P, Tewary A, Dixit A, Pandey AK, Benjamin M, Tanwar P, Dey A, Khan F, Pandey P. Immunological mechanisms of vaccine-induced protection against SARS-CoV-2 in humans. Immuno. 2021;1(4):442\u201356. https:\/\/doi.org\/10.3390\/immuno1040032.","journal-title":"Immuno"},{"key":"9265_CR151","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3390\/v2081681","volume":"2","author":"I Kovesdi","year":"2010","unstructured":"Kovesdi I, Hedley SJ. Adenoviral producer cells. Vaccine. 2010;2:1681\u2013703. https:\/\/doi.org\/10.3390\/v2081681.","journal-title":"Vaccine"},{"key":"9265_CR152","doi-asserted-by":"publisher","first-page":"198466","DOI":"10.1016\/j.virusres.2021.198466","volume":"302","author":"W Doerfler","year":"2021","unstructured":"Doerfler W. Adenoviral vector DNA-and SARS-CoV-2 mRNA-based COVID-19 vaccines: possible integration into the human genome-are adenoviral genes expressed in vector-based vaccines? Virus Res. 2021;302:198466. https:\/\/doi.org\/10.1016\/j.virusres.2021.198466.","journal-title":"Virus Res"},{"issue":"1","key":"9265_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-00352-y","volume":"5","author":"Y Dong","year":"2020","unstructured":"Dong Y, Dai T, Wei Y, Zhang L, Zheng M, Zhou F. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1):1\u20134. https:\/\/doi.org\/10.1038\/s41392-020-00352-y.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"9265_CR154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-021-03662-x","volume":"25","author":"J Khateeb","year":"2021","unstructured":"Khateeb J, Li Y, Zhang H. Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Crit Care. 2021;25(1):1\u20138. https:\/\/doi.org\/10.1186\/s13054-021-03662-x.","journal-title":"Crit Care"},{"issue":"9","key":"9265_CR155","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran WF, Lam EC, Denis KS, Nitido AD, Garcia ZH, Hauser BM, Feldman J, Pavlovic MN, Gregory DJ, Poznansky MC, Sigal A. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):2372\u201383. https:\/\/doi.org\/10.1016\/j.cell.2021.03.013.","journal-title":"Cell"},{"issue":"7","key":"9265_CR156","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.3390\/microorganisms9071542","volume":"9","author":"S Cherian","year":"2021","unstructured":"Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M, Rakshit P, Singh S, Abraham P, Panda S, Team NI. SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. Microorganisms. 2021;9(7):1542. https:\/\/doi.org\/10.3390\/microorganisms9071542.","journal-title":"Microorganisms"},{"key":"9265_CR157","doi-asserted-by":"publisher","first-page":"1","DOI":"10.25259\/IJMS_157_2021","volume":"73","author":"SR Joshi","year":"2021","unstructured":"Joshi SR, Pandit R, Parikh P, Gulia A. Containing COVID-19 second surge in India. Indian J Med Sci. 2021;73:1. https:\/\/doi.org\/10.25259\/IJMS_157_2021.","journal-title":"Indian J Med Sci"},{"issue":"4","key":"9265_CR158","first-page":"261","volume":"3","author":"JP Sahoo","year":"2021","unstructured":"Sahoo JP, Mishra AP, Samal KC. Triple mutant Bengal strain (B. 1.618) of coronavirus and the worst COVID outbreak in India. Biol Res Tod. 2021;3(4):261\u20135.","journal-title":"Biol Res Tod"},{"key":"9265_CR159","unstructured":"Aleem A, AB AS, Slenker AK. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)."},{"key":"9265_CR160","doi-asserted-by":"publisher","first-page":"102715","DOI":"10.1016\/j.jaut.2021.102715","volume":"124","author":"SR Kannan","year":"2021","unstructured":"Kannan SR, Spratt AN, Cohen AR, Naqvi SH, Chand HS, Quinn TP, Lorson CL, Byrareddy SN, Singh K. Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses. J Autoimmun. 2021;124:102715. https:\/\/doi.org\/10.1016\/j.jaut.2021.102715.","journal-title":"J Autoimmun"},{"key":"9265_CR161","doi-asserted-by":"publisher","unstructured":"Mahase E. COVID-19: do vaccines work against omicron\u2014and other questions answered. BMJ\u00a02021;\u00a0375 https:\/\/doi.org\/10.1136\/bmj.n3062","DOI":"10.1136\/bmj.n3062"},{"issue":"6","key":"9265_CR162","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3390\/vaccines9060616","volume":"9","author":"NS Zuckerman","year":"2021","unstructured":"Zuckerman NS, Fleishon S, Bucris E, Bar-Ilan D, Linial M, Bar-Or I, Indenbaum V, Weil M, Lustig Y, Mendelson E, Mandelboim M. A unique SARS-CoV-2 spike protein P681H variant detected in Israel. Vaccines. 2021;9(6):616. https:\/\/doi.org\/10.3390\/vaccines9060616.","journal-title":"Vaccines"},{"issue":"27","key":"9265_CR163","doi-asserted-by":"publisher","first-page":"E1059","DOI":"10.1503\/cmaj.1095949","volume":"193","author":"D Duong","year":"2021","unstructured":"Duong D. Alpha, Beta, Delta, Gamma: what\u2019s important to know about SARS-CoV-2 variants of concern? Can Med Assoc J. 2021;193(27):E1059\u201360. https:\/\/doi.org\/10.1503\/cmaj.1095949.","journal-title":"Can Med Assoc J"},{"issue":"20","key":"9265_CR164","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","volume":"384","author":"SA Madhi","year":"2021","unstructured":"Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, Briner C. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant. N Engl J Med. 2021;384(20):1885\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2102214.","journal-title":"N Engl J Med"},{"issue":"372","key":"9265_CR165","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1101\/2021.02.26.21252554","volume":"12","author":"NR Faria","year":"2021","unstructured":"Faria NR, Claro IM, Candido D, Franco LM, Andrade PS, Coletti TM, Silva CA, Sales FC, Manuli ER, Aguiar RS, Gaburo N. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. Virological. 2021;12(372):815\u201321. https:\/\/doi.org\/10.1101\/2021.02.26.21252554.","journal-title":"Virological"},{"key":"9265_CR166","unstructured":"American society of microbiology. How-Dangerous-is-the-Delta-Variant-B-1\u2013617\u20132. https:\/\/asm.org\/Articles\/2021\/July. (Accessed in 15th December, 2021)."},{"key":"9265_CR167","doi-asserted-by":"publisher","first-page":"e068848","DOI":"10.1136\/bmj-2021-068848","volume":"375","author":"K Bruxvoort","year":"2021","unstructured":"Bruxvoort K, Sy LS, Qian L, Ackerson BK, Luo Y, Lee GS, Tian Y, Florea A, Aragones M, Tubert JE, Takhar HS. Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants. medRxiv. 2021;375:e068848. https:\/\/doi.org\/10.1136\/bmj-2021-068848.","journal-title":"medRxiv"},{"key":"9265_CR168","unstructured":"Wadman M. California coronavirus strain may be more infectious\u2014and lethal. Science. 2021 (Accessed in 15th December, 2021)."},{"issue":"13","key":"9265_CR169","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/jama.2021.1612","volume":"325","author":"W Zhang","year":"2021","unstructured":"Zhang W, Davis BD, Chen SS, Martinez JM, Plummer JT, Vail E. Emergence of a novel SARS-CoV-2 variant in Southern California. JAMA Netw Open. 2021;325(13):1324\u20136. https:\/\/doi.org\/10.1001\/jama.2021.1612.","journal-title":"JAMA Netw Open"},{"key":"9265_CR170","unstructured":"World Health Organization. Tracking SARS-CoV-2 variants. https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/ WHO. (Accessed in 15th December, 2021)."},{"key":"9265_CR171","doi-asserted-by":"publisher","unstructured":"Kimura I, Kosugi Y, Wu J, Yamasoba D, Butlertanaka EP, Tanaka YL, Liu Y, Shirakawa K, Kazuma Y, Nomura R, Horisawa Y. SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance. BioRxiv.2021 Jan 1. https:\/\/doi.org\/10.1101\/2021.07.28.454085","DOI":"10.1101\/2021.07.28.454085"},{"key":"9265_CR172","unstructured":"Outbreak. Info. Lineage. Mutation Tracker, Mu Variant Report. https:\/\/outbreak.info\/situation-reports\/Mu (Accessed in 15th December, 2021)."},{"key":"9265_CR173","doi-asserted-by":"publisher","unstructured":"Fratev F. The R346K mutation in the Mu variant of SARS-CoV-2 alter the interactions with monoclonal antibodies from class 2: a free energy of perturbation study. BioRxiv. 2021 https:\/\/doi.org\/10.1101\/2021.10.12.463781","DOI":"10.1101\/2021.10.12.463781"},{"key":"9265_CR174","unstructured":"UK Health Security Agency. SARS-CoV WH. Variants of concern and variants of interest, updated 31 May 2021. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1042367\/technical_briefing-31-10-december-2021.pdf. (Accessed in 19th December, 2021)."},{"key":"9265_CR175","unstructured":"Pfize. Pfizer and BioNTech provide update on Omicron variant. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-provide-update-omicron-variant (Accessed in 19th December, 2021)."},{"key":"9265_CR176","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/jtm\/taab051","volume":"28","author":"GN Sapkal","year":"2021","unstructured":"Sapkal GN, Yadav PD, Ella R, Deshpande GR, Sahay RR, Gupta N, Vadrevu KM, Abraham P, Panda S, Bhargava B. Inactivated COVID-19 vaccine BBV152\/COVAXIN effectively neutralizes recently emerged B. 1.1. 7 variant of SARS-CoV-2. J Trav Med. 2021;28:51. https:\/\/doi.org\/10.1093\/jtm\/taab051.","journal-title":"J. Trav Med"},{"key":"9265_CR177","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(21)00468-2","volume":"397","author":"SS Karim","year":"2021","unstructured":"Karim SS. Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection. Lancet. 2021;397:1263\u20134. https:\/\/doi.org\/10.1016\/S0140-6736(21)00468-2.","journal-title":"Lancet"},{"issue":"3","key":"9265_CR178","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.tracli.2021.05.005","volume":"28","author":"B Bhasker","year":"2021","unstructured":"Bhasker B. COVID 19 vaccination: latest guidelines on blood donor deferral in India. Transfus Clin Biol. 2021;28(3):299. https:\/\/doi.org\/10.1016\/j.tracli.2021.05.005.","journal-title":"Transfus Clin Biol"},{"key":"9265_CR179","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13577-021-00512-4","volume":"7","author":"S Kashte","year":"2021","unstructured":"Kashte S, Gulbake A, El-Amin SF III, Gupta A. COVID-19 vaccines: rapid development, implications, challenges and future prospects. Hum cell. 2021;7:1\u201323. https:\/\/doi.org\/10.1007\/s13577-021-00512-4.","journal-title":"Hum cell"},{"issue":"4","key":"9265_CR180","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","volume":"33","author":"RL Coffman","year":"2010","unstructured":"Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33(4):492\u2013503. https:\/\/doi.org\/10.1016\/j.immuni.2010.10.002.","journal-title":"Immunity"},{"key":"9265_CR181","doi-asserted-by":"publisher","first-page":"198114","DOI":"10.1016\/j.virusres.2020.198114","volume":"13","author":"SP Kaur","year":"2020","unstructured":"Kaur SP, Gupta V. COVID-19 vaccine: a comprehensive status report. Virus Res. 2020;13:198114. https:\/\/doi.org\/10.1016\/j.virusres.2020.198114.","journal-title":"Virus Res"},{"key":"9265_CR182","doi-asserted-by":"publisher","unstructured":"Jayadevan R, Shenoy RS, Anithadevi TS. Survey of symptoms following COVID-19 vaccination in India.Medrxiv.2021 .https:\/\/doi.org\/10.1101\/2021.02.08.21251366","DOI":"10.1101\/2021.02.08.21251366"},{"key":"9265_CR183","unstructured":"COVAXIN Factsheet-V4. Restricted use in emergency situation of COVID-19. https:\/\/www.bharatbiotech.com\/images\/covaxin\/covaxin-factsheet.pdf (Accessed 19th December, 2021)."},{"key":"9265_CR184","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0140-6736(21)00191-4","volume":"397","author":"I Jones","year":"2021","unstructured":"Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet. 2021;397:642\u20133. https:\/\/doi.org\/10.1016\/S0140-6736(21)00191-4.","journal-title":"Lancet"},{"issue":"10275","key":"9265_CR185","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"DY Logunov","year":"2021","unstructured":"Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(21)00234-8.","journal-title":"Lancet"},{"issue":"34","key":"9265_CR186","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1016\/j.vaccine.2020.06.022","volume":"38","author":"S Pagliusi","year":"2020","unstructured":"Pagliusi S, Jarrett S, Hayman B, Kreysa U, Prasad SD, Reers M, Thai PH, Wu K, Zhang YT, Baek YO, Kumar A. Emerging manufacturers engagements in the COVID\u2212 19 vaccine research, development and supply. Vaccine. 2020;38(34):5418\u201323. https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.022.","journal-title":"Vaccine"},{"key":"9265_CR187","doi-asserted-by":"publisher","unstructured":"Sharun K, Dhama K. India\u2019s role in COVID-19 vaccine diplomacy. J.\u00a0Travel Med. 2021 https:\/\/doi.org\/10.1093\/jtm\/taab064","DOI":"10.1093\/jtm\/taab064"},{"issue":"11","key":"9265_CR188","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1016\/j.drudis.2021.07.021","volume":"26","author":"VP Chavda","year":"2021","unstructured":"Chavda VP, Vora LK, Pandya AK, Patravale VB. Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management. Drug Discov Today. 2021;26(11):2619\u201336. https:\/\/doi.org\/10.1016\/j.drudis.2021.07.021.","journal-title":"Drug Discov Today"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-022-09265-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-022-09265-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-022-09265-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:39:47Z","timestamp":1744198787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-022-09265-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":188,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["9265"],"URL":"https:\/\/doi.org\/10.1007\/s12026-022-09265-0","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]},"assertion":[{"value":"25 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}